Biosimilar Development: From Phase III to Analytical Comparability and PK/PD
Although the development of biosimilars has historically been difficult, expensive, [...]
OligoXplorer: Our CMC Platform for Oligonucleotide Therapeutics
Oligonucleotide-based therapeutics have become one of the most promising [...]